MET DNA Alterations in NSCLC-Reply.

نویسندگان

  • Joanna H M Tong
  • Anthony W H Chan
  • Ka F To
چکیده

We thank Mengoli and colleagues for their interest in our article (1) and their comprehensive review of METD14-positive pulmonary sarcomatoid carcinomas (PSC) been reported in the literature. We agree with their observation that METD14 seems to be associated with the presence of adenocarcinoma component. Of the 7 METD14-positive PSCs in our series, 5 contain adenocarcinoma components admixed with sarcomatous components (giant cell or spindle cell). These include four with adenocarcinoma (TTF-1 positive) and one with adenosquamous cell carcinoma (ADSQ, TTF-1, p40, and p63 positive). These 5 cases can be classified as pleomorphic carcinoma according to the 2015 WHO classification of lung tumors (2). For the other two METD14-positive tumors, one shows pure giant cell morphology but exhibits focal positivity for TTF-1. Although focal TTF-1 expression might suggest the differentiation toward adenocarcinoma, we diagnosed this tumor as giant cell carcinoma rather than pleomorphic carcinoma due to the absence of adenocarcinoma morphology. The remaining METD14-positive tumor is a pure spindle cell carcinoma that is positive for cytokeratin and negative for TTF-1. An interesting observation of our cases is the presence of METD14 in both epithelial and sarcomatous components in four pleomorphic carcinomas that we analyzed the two components separately (unpublished data), suggesting the clonal origin of the two components. However, in two tumors with concomitant METD14 and high-level MET amplification, MET amplification is found in sarcomatous component only but not in epithelial elements (case #4 and #16 in Supplementary Table S2 of the original article; ref. 1). This is in keeping with the monoclonal theory of biphasic tumors (3) and the sarcomatous elements might derive from the carcinoma during the evolution of the tumor. In keeping with other studies (4) that METD14 associates with adenocarcinoma component, 5 of 7 PSCs in our series contain adenocarcinoma component. METD14 can also be found in pure giant cell (n 1⁄4 1) and spindle cell carcinoma (n 1⁄4 1). Although there is no statistically significant association between the presence of adenocarcinoma component and METD14 (Table 1, P 1⁄4 0.074) in PSC, a trend toward higher

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

The hepatocyte growth factor receptor (MET) is a potential therapeutic target in a number of cancers, including NSCLC. In NSCLC, MET pathway activation is thought to occur through a diverse set of mechanisms that influence properties affecting cancer cell survival, growth, and invasiveness. Preclinical and clinical evidence suggests a role for MET activation as both a primary oncogenic driver i...

متن کامل

Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations

BACKGROUND Selection of NSCLC patients for targeted therapy is currently based upon the presence of sensitizing mutations in EGFR and EML4/ALK translocations. The heterogeneity of molecular alterations in lung cancer has led to the ongoing discovery of potential biomarkers and targets in order to improve survival. AIM This study aimed to detect alterations in EGFR, KRAS, BRAF, PIK3CA, MET-gen...

متن کامل

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.

PURPOSE Tumor genotyping is a powerful tool for guiding non-small cell lung cancer (NSCLC) care; however, comprehensive tumor genotyping can be logistically cumbersome. To facilitate genotyping, we developed a next-generation sequencing (NGS) assay using a desktop sequencer to detect actionable mutations and rearrangements in cell-free plasma DNA (cfDNA). EXPERIMENTAL DESIGN An NGS panel was ...

متن کامل

Therapeutic Inhibition with SU11274 and Small Interfering Functional Expression and Mutations of c-Met and Its

Non–small cell lung cancer (NSCLC) is a difficult disease to treat. The c-Met receptor is an attractive potential target for novel therapeutic inhibition in human cancers. We provide strong evidence that c-Met is overexpressed, activated, and sometimes mutated in NSCLC cell lines and tumor tissues. Expression of c-Met was found in all (100%) of the NSCLC tumor tissues examined (n = 23) and most...

متن کامل

Tumor molecular profiling of NSCLC patients using next generation sequencing

Non‑small cell lung cancer (NSCLC) is the most common type of lung cancer and a tumor with a broad spectrum of targeted therapies already available or in clinical trials. Thus, molecular characterization of the tumor using next generation sequencing (NGS) technology, has become a key tool for facilitating treatment decisions and the clinical management of NSCLC patients. The performance of a cu...

متن کامل

MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review

The alterations of MET have been detected in non-small-cell lung cancer (NSCLC). However, survival benefit of MET inhibitors remains controversial. We performed this meta-analysis to evaluate the survival benefit of MET inhibitors combined with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) or standard chemotherapy in patients with advanced or metastatic NSCLC. A syste...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Clinical cancer research : an official journal of the American Association for Cancer Research

دوره 22 14  شماره 

صفحات  -

تاریخ انتشار 2016